Compare Domino's Pizza, Inc. (DPZ) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Novavax Inc — how do they compare? Domino's Pizza, Inc. trades at $352.51 (market cap $11.82B), while Novavax Inc trades at $7.94 (market cap $1.31B). The key difference: Domino's Pizza, Inc. is far larger — about 9× Novavax Inc's market cap, and Domino's Pizza, Inc. pays a 2.23% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| DPZ | NVAX | |
|---|---|---|
Market Cap | $11.82B | $1.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $467.30 | $11.19 |
52-Week Low | $282.89 | $6.22 |
Enterprise Value | $16.78B | $889.30M |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DPZ trades at $353.57, up 1.64% today, with bullish technical signals from moving averages and a consensus analyst price target of $371.67. Recent earnings missed expectations in Q2 2026, but revenue grew to $4.94B in 2025 with a net income margin of 11.86%. The company launched a new individual-size pizza in August 2026 to boost sales, while high debt levels and weak premium pizza demand pose challenges.
The outlook is cautiously optimistic, supported by analyst buy ratings (53.85%) and innovation initiatives, but risks include rising input costs, competitive pressures, and insider selling. Investors should weigh strong cash flow generation against debt sustainability for long-term value.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
